Linked Life Data

9829838

Source:http://linkedlifedata.com/resource/pubmed/id/9829838

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-12-3
pubmed:abstractText
Eighteen colorectal carcinoma patients without macroscopic disease after surgery were immunized using recombinant (r) human (h) carcinoembryonic antigen (CEA) with (n=9) or without (n=9) the addition of soluble granulocyte/macrophage-colony-stimulating factor (GM-CSF). The dose of rhCEA per immunization was 100 microg (n=6), 316 microg (n=6) or 1000 microg (n=6). rhCEA was given s.c. on day 1 and 80 microg/day of GM-CSF s.c. on days 1-4. The schedule was repeated six times during a period of 9 months. All patients in the GM-CSF group developed a strong rhCEA-dose-dependent IgG antibody response while only one-third of the non-GM-CSF patients mounted a weak antibody response. All patients (9/9) in the GM-CSF group developed a strong rhCEA-specific proliferative T cell response as well as type I T cells (interferon gamma secretion). In 45% of the patients also a weak type II T cell response (interleukin-4 secretion) was evoked. Both MHC-class-I- and -II restricted rhCEA-specific T cells were noted. A specific cellular response (proliferation and/or cytokine secretion) against native hCEA could be found in 8/9 patients in the GM-CSF group, although at a significantly lower level than against rhCEA. In the non-GM-CSF group a weak rhCEA-specific T cell response was induced. Three patients had a proliferative response, 4 patients type I T cells and 6 patients type II T cells. No signs of autoimmune reactions were noted. Local pharmacological administration of GM-CSF seemed to be a prerequisite for the induction of a strong immunity against baculovirus-produced hCEA protein. However, the cellular response against native CEA was of a significantly lower magnitude.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
131-42
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9829838-Adjuvants, Immunologic, pubmed-meshheading:9829838-Adult, pubmed-meshheading:9829838-Aged, pubmed-meshheading:9829838-Antibodies, Neoplasm, pubmed-meshheading:9829838-Cancer Vaccines, pubmed-meshheading:9829838-Carcinoembryonic Antigen, pubmed-meshheading:9829838-Carcinoma, pubmed-meshheading:9829838-Colorectal Neoplasms, pubmed-meshheading:9829838-Female, pubmed-meshheading:9829838-Granulocyte-Macrophage Colony-Stimulating Factor, pubmed-meshheading:9829838-Histocompatibility Antigens Class I, pubmed-meshheading:9829838-Histocompatibility Antigens Class II, pubmed-meshheading:9829838-Humans, pubmed-meshheading:9829838-Immunity, Cellular, pubmed-meshheading:9829838-Lymphocyte Activation, pubmed-meshheading:9829838-Male, pubmed-meshheading:9829838-Middle Aged, pubmed-meshheading:9829838-T-Lymphocytes, pubmed-meshheading:9829838-Time Factors, pubmed-meshheading:9829838-Vaccination, pubmed-meshheading:9829838-Vaccines, Synthetic
pubmed:year
1998
pubmed:articleTitle
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
pubmed:affiliation
Department of Oncology, Karolinska Hospital, Stockholm, Sweden.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't